Diagnostic Technologies Ltd.

Diagnostic Technologies Ltd. is a medical diagnostic and biotechnology company incubated at the Technion - Israeli Institute of Technology in 1994 and emerged as an independent company in 2001.

DTL's lead product is placental protein-13 (PP13) - a sensitive and selective biomarker to screen for preeclampsia, intrauterine growth restriction and preterm delivery.

Pregnancy at Risk: Preeclampsia

Preeclampsia, a multi-system disorder, complicates 5-7% of all pregnancies, and is responsible for 18% of maternal deaths during pregnancy, and for a 1/3 of prematurity.

Recent Press Release

Grant Life Sciences enters into a Memorandum of Understanding with Diagnostic Technologies Ltd. to develop and commercialize Grant's cervical cancer-diagnostic technology.